Respiratory Emergencies,

(1) Acute Severe Asthma:

According to Tintinalli, acute severe asthma—also termed status asthmaticus—is a
life-threatening exacerbation that fails to respond to standard inhaled bronchodilators
and corticosteroids, and requires urgent intervention

Key presentation features include:

 Severe dyspnea and tachypnea that prevent completing sentences.

 Use of accessory muscles, difficulty speaking, and possible chest tightness.
 Reduced oxygen saturation often below 92%, silent chest (minimal air movement),
exhaustion, drowsiness—signs of impending respiratory failure

🚑 Stepwise Management Approach

1. Immediate Resuscitation & Monitoring

 Provide high-concentration O₂ to maintain sats ≥ 92%.

 Initiate continuous monitoring (pulse oximetry, HR, respiratory rate, noninvasive or
invasive blood pressure).
 Establish IV access and collect early blood gas if needed.

2. Initial Pharmacotherapy

 Short-acting β₂ agonists (SABA): Inhaled salbutamol (albuterol) via nebulizer or

MDI with spacer—first-line rescue therapy
 Inhaled ipratropium bromide: Added in moderate-to-severe attacks to enhance
bronchodilation
 Systemic corticosteroids: Administer IV methylprednisolone or oral prednisolone
early to reduce airway inflammation—critical even if improvement seems imminent

3. Escalation Therapy for Persistent Severe Distress

If symptoms persist or worsen:

 Continuous nebulized β₂ agonist therapy.

 IV magnesium sulfate: Rapid bronchodilator in severe cases not responding to
conventional therapy
 Additional adjuncts:
o In certain settings: IV terbutaline or aminophylline infusion.
o Consider heliox, non-invasive ventilation (BiPAP/CPAP) to reduce work of
breathing
o Ketamine infusion may be used both as sedation and bronchodilator in
patients on non-invasive ventilation or before intubation

4. Refractory Status Asthmaticus

For children failing to respond to second-line therapy:

 Prepare for endotracheal intubation and mechanical ventilation with appropriate

bronchodilator and sedation coverage.
 Use anesthetics like ketamine or propofol for their bronchodilating and sedating
effects during ventilation transitions
 Continue critical care management with ventilation strategies to avoid barotrauma and
permit permissive hypercapnia if necessary.

📊 Summary Table
Phase Intervention
O₂ to maintain SpO₂ ≥ 92%; IV access; vital signs and
Initial Stabilization
cardiorespiratory monitoring
First-line (0–
Inhaled SABA + ipratropium; early systemic steroids
10 min)
Escalation (10– Continuous nebulization; IV magnesium sulfate; adjuncts such as
30 min) aminophylline or heliox; ketamine
Refractory Intubation, mechanical ventilation, sedation/anesthesia, ICU-level
(>30 min) support

✅ Clinical Pearls
 Time is critical: Early administration of corticosteroids and bronchodilators can
dramatically reduce progression.
 Adjunct therapies (magnesium sulfate, aminophylline, heliox) may salvage severe
cases when first-line response is inadequate.
 Ketamine offers dual benefit as a sedative and bronchodilator during NIV support or
pre-intubation.
 Continuous assessment using severity scoring and vigilant monitoring helps guide
escalation decisions.
 Sedation and advanced airway support must be balanced with ventilator strategies to
minimize barotrauma and hemodynamic compromise.

(2)COPD Acute Exacerbation:

An acute exacerbation of COPD (AECOPD) is defined as a sudden worsening of

respiratory symptoms—such as dyspnea, cough, or sputum—beyond daily variability that
requires a change in medication or intervention. The chief objectives of management include:

 Correct tissue oxygenation

 Relieve reversible bronchospasm
 Identify and treat underlying triggers
🩺 Initial Stabilization & Monitoring
 Provide supplemental oxygen, targeting PaO₂ > 60 mm Hg or SpO₂ > 90%, while
avoiding hyperoxia and CO₂ retention. Monitor via ABGs and serial assessments
 Continuously observe vital signs and mental status; establish IV access for
medications and fluids if needed.

💨 Bronchodilator Therapy
🟢 First-Line Agents

 Inhaled β₂ agonists (e.g., nebulized or MDI salbutamol/albuterol): delivered every

30–60 minutes as needed; monitor for side effects such as tremor or tachyarrhythmia,
particularly in patients with underlying heart disease
 Inhaled anticholinergics (e.g. ipratropium, glycopyrrolate): additive therapy standard
in COPD management

These inhaled treatments are preferred to minimize systemic side effects.

🧴 Corticosteroids & Antibiotics

 Administer systemic corticosteroids early (oral or IV)—typically prednisone or
methylprednisolone—shortening recovery and reducing relapse rate. A 5-day course
often suffices compared to longer durations
 Antibiotics are indicated if patients have increased sputum production, purulence,
fever, elevated WBC, or radiographic infiltrates suggestive of bacterial infection.
Outpatient regimens include amoxicillin, doxycycline, or co-trimoxazole, and in more
complex cases—amoxiclav, cefuroxime or fluoroquinolones

🚑 Escalation & Advanced Support

 If hypoxia persists or respiratory acidosis develops (especially with rising PaCO₂),
escalate to non-invasive ventilation (NIV) (e.g., BiPAP/CPAP). If ineffective or
contraindicated, intubation and mechanical ventilation may be required
 Theophylline is generally not recommended due to limited benefit and narrow
therapeutic window; check drug levels if the patient is already on it.
🧪 Diagnostic Evaluation & Trigger Workup
 Review baseline spirometry if available, assess prior hospitalizations or exacerbation
history, and evaluate for comorbid conditions or medication toxicity.
 Order labs and imaging judiciously:
o CBC, electrolytes, BNP if heart failure is a concern
o ECG and chest imaging or CT if pneumonia or pulmonary embolism is
suspected
o Theophylline level if relevant

📋 Management Summary Table

Phase Intervention
Stabilization Oxygen titration (SpO₂ > 90%), IV access, monitoring
Bronchodilators Inhaled β₂ agonists (q30–60 min PRN) + anticholinergics
Anti-inflammatory + Systemic steroids (short course), antibiotics if
ABX purulence/fever/WBC rise
NIV (BiPAP/CPAP) or mechanical ventilation if respiratory
Escalation
failure ensues
Diagnostics & Triggers Labs, imaging, cultures, review spirometry/sputum if indicated

✅ Clinical Pearls
 Balance oxygen therapy: both hypoxia and excessive O₂ can be harmful—target
SpO₂ carefully.
 Prompt corticosteroid therapy shortens recovery and reduces relapse.
 Reserve antibiotics for likely bacterial exacerbations—avoid overuse.
 Early NIV can prevent the need for intubation and ICU admission in many patients.
 Individualized management is key: take into account previous exacerbations,
spirometry, current meds, and comorbidities.

(3)Pneumothorax:

Tintinalli describes pneumothorax as a condition where air accumulates in the pleural

space, leading to partial or complete lung collapse. It includes:

 Primary spontaneous pneumothorax (PSP): in typically healthy individuals

without lung disease.
 Secondary spontaneous pneumothorax (SSP): occurring in patients with underlying
lung pathology (e.g. COPD, cystic disease)
 Traumatic pneumothorax, including iatrogenic causes.
 Tension pneumothorax: life-threatening form with mediastinal shift and
hemodynamic compromise—diagnosed clinically and requiring immediate
intervention
Key signs:

 Sudden pleuritic chest pain, dyspnea, diminished or absent breath sounds unilaterally,
hyperresonance.
 In tension physiology: hypotension, tachycardia, jugular venous distention, altered
mental status

🔍 Diagnosis
 Chest X-ray (upright, full inspiration) is the standard initial diagnostic tool—
however, small pneumothoraces may be missed.
 Point-of-care ultrasound (POCUS) is highlighted by Tintinalli as highly sensitive
for early detection of pneumothorax, even in supine trauma settings. It identifies
lung-sliding absence, “lung point”, and the barcode sign
 CT scanning reserved for occult pneumothoraces or when underlying lung disease is
suspected (e.g. bullae)

🩺 Management Strategy
⚡ Tension Pneumothorax (Emergency):

 Immediate needle decompression without imaging delay:

o Use ≥14G, ≥5 cm catheter.
o Insert at 4th–5th intercostal space, anterior axillary line (preferred over 2nd
ICS MCL due to lower failure rate), or perform finger thoracostomy.
 Follow with chest tube thoracostomy as definitive control.

🟢 Non-Tension Pneumothorax:

 Small, primary spontaneous, stable pneumothorax (<2–3 cm rim):

o Administer 100% oxygen to accelerate reabsorption (~4× improvement).
o Observe with serial imaging and may allow outpatient management if
improving
 Moderate-to-large or symptomatic pneumothorax:
o Needle aspiration or small-bore pigtail catheter as initial intervention—can
be as effective as traditional larger chest tubes.
o Admit for observation with repeat chest imaging within 4 hours and follow-up
care

🟡 Secondary or Traumatic Pneumothorax:

 Almost always requires chest tube placement, especially in SSP or traumatic causes,
even if small, due to higher risk of deterioration.
  Chest tube inserted in 5th-6th intercostal space, mid- or anterior axillary line,
connected to water seal under suction.
 Provide analgesia and local anaesthetic before procedure; sedation as needed

🔄 Escalation & Further Considerations

 If persistent air leak or failure of lung re-expansion:
o Assess chest tube position, suction system.
o Consider surgery evaluation or ambulatory drainage devices.
 Recurrent pneumothorax may warrant pleurodesis (e.g. talc, blood patch) or
surgical options like VATS
 Provide adequate pain control, both systemic and local (e.g. intercostal block),
especially for tube placement; consider prophylactic antibiotics per institutional
protocols to reduce infection risk

📋 Summary Table
Scenario Management Approach
Immediate needle decompression (4–5 ICS AAL) → Chest
Tension pneumothorax
tube
High-flow O₂ + observation ± aspiration, repeat imaging,
Small PSP, stable
possible outpatient care
Moderate/large PSP or Needle aspiration or small-bore catheter, admission, serial
symptomatic imaging
Secondary or traumatic Chest tube thoracostomy (tube size based on needs),
pneumothorax analgesia, hospital admission
Persistent leak or recurrence Evaluate for surgery or pleurodesis

✅ Clinical Pearls
 A tension pneumothorax is a clinical diagnosis—do not await imaging if
hemodynamic compromise is evident.
 POCUS is invaluable for early detection, particularly in trauma or supine patients.
 Supplemental O₂ not only improves hypoxia but also accelerates air reabsorption in
pneumothorax.
 Opt for small-bore catheters or aspiration when appropriate—they reduce patient
discomfort and can decrease hospital stays.
 Chest tubes still standard in SSP or trauma, and in persistent or recurrent cases
where invasive drainage or surgical intervention may be necessary.

(4)Foreign body aspiration:

Clinical Presentation & Recognition
 Foreign body aspiration (FBA) should be suspected in children under 5 years,
especially toddlers, who present with sudden choking, coughing, wheezing, stridor,
or unilateral breath sounds—often witnessed or following a high-risk ingestion
episode. These can include peanuts, coins, toy parts, candies, and similar small
objects.
 Key exam findings vary by location:
o Upper airway (supraglottic/tracheal): stridor, hoarseness, drooling
o Lower airway: localized wheeze, asymmetrical air entry, possible recurrent
pneumonia.

🔍 Initial Assessment
1. Primary Survey & Airway Support (ABC)
o Do not perform blind finger sweeps—it risks further impaction. Use direct
visualization or suction if necessary.
o In infants (<1 year) with complete obstruction: alternate 5 back blows
followed by 5 chest thrusts.
o In children >1 year: perform Heimlich maneuver for complete obstruction
cases.
2. Evaluation when the patient is stable
o Obtain a thorough history, ideally from a witness, as symptoms may mimic
asthma, pneumonia, or croup.
o Perform thoracic imaging:
 AP and lateral chest and neck films.
 Decubitus or expiratory radiographs if lower airway obstruction is
suspected—looking for unilateral air-trapping, atelectasis, or
mediastinal shift. However, up to 50% of CXRs may be normal even
with FBA.

🛠 Definitive Management
 Rigid bronchoscopy under general anesthesia is the gold-standard for both
diagnosis and removal of aspirated foreign bodies—due to optimal airway control,
visualization, and instrument versatility. Success rates are approximately 95–98%,
with low complication rates.
 Flexible bronchoscopy may be considered (especially for distal objects or when
diagnosis is unclear)—but rigid bronchoscopy should be available on standby given
risk of migration or incomplete extraction.

At-Risk or Complicated Scenarios:

  In cases of complete obstruction during attempted removal, the FB may be pushed
into a bronchus to ventilate the other lung as a rescue method.
 In instances of airway trauma or bronchial injury, advanced airway techniques
(e.g., distal ETT placement, double-lumen tubes, or even ECMO/CPB) may be
required.

🧪 Post-Removal Care & Observation

 After extraction, patients may receive nebulized β₂ agonists and chest
physiotherapy to aid in airway clearance.
 Steroids or antibiotics are not routinely needed, but can be used if surrounding
inflammation or infection is present—or when removal is delayed.
 Most clinically stable pediatric patients can be discharged within 24 hours if no
complications and oxygen is not required. Routine follow-up imaging is not always
necessary unless symptoms persist.

📋 Summary Table
Scenario Key Intervention
Complete upper airway Back blows/chest thrusts (<1 yr), or Heimlich (>1 yr); avoid
obstruction blind finger sweep
Suspected lower airway
History + exam + imaging (CXR ± decubitus films)
FBA
Confirmed or high
Rigid bronchoscopy under GA for removal
suspicion FBA
Distal or unclear FBA Consider flexible bronchoscopy with rigid standby
Advanced airway strategies, surgical consultation, possible
Complicated airway injury
ECMO/CPB support
Nebulized bronchodilators, physiotherapy; steroids/antibiotics
Post-extraction
if indicated; admit if unstable

✅ Key Clinical Pearls

 FBA should be presumed with sudden onset of choking and unilateral
respiratory signs in young children—even if imaging is normal.
 Never do blind finger sweeps; use direct visualization or suction under caution.
 Rigid bronchoscopy remains the mainstay: ideal for airway control and object
retrieval.
 Post-removal therapy and observation optimize outcomes and reduce
complications such as airway edema or infection.
 Rapid diagnosis and removal minimize risk of serious outcomes like pneumonia,
pneumothorax, or death.
 (5) ARDS and non-invasive ventilation:
Acute respiratory distress syndrome (ARDS) is a type of respiratory
failure characterized by rapid onset of widespread inflammation in the lungs.
Symptoms include shortness of breath (dyspnea), rapid
breathing (tachypnea), and bluish skin coloration (cyanosis).

Tintinalli focuses on invasive low-tidal volume ventilation (6 ml/kg PBW), reliable

PEEP, and fluid-conservative strategies, it acknowledges emerging therapies such as prone
positioning and extracorporeal membrane oxygenation (ECMO) for refractory cases. The text
also discusses non-invasive ventilation as a modality, particularly for select populations
like COPD patients.

🛠 The Role of Non-Invasive Ventilation in ARDS

Physiological Basis

NIV can:

 Provide positive airway pressure (CPAP or BiPAP modes)

 Help maintain end-expiratory lung volume (EELV)
 Reduce the work of breathing and improve oxygenation in early or mild ARDS cases

However, NIV is intermittent support, and mask interfaces limit sustained high PEEP
necessary to prevent alveolar collapse over long periods.

Clinical Evidence & Limitations

 Randomized controlled data are limited and heterogeneous. One RCT in early
pneumonia-induced mild ARDS showed no significant mortality/intubation benefit
from NIV compared to Venturi mask therapy
 Other meta-analyses suggest unselected ARDS patients have high NIV failure
rates (~48%) and that failure is associated with increased mortality—particularly in
moderate to severe ARDS (PaO₂/FiO₂ <150)

Who Might Benefit?

 Highly selected patients with mild ARDS, where PaO₂/FiO₂ >150–175 and early
response to NIV within the first hour.
 Immunocompromised patients, where NIV may reduce intubation rates and ICU
length of stay compared to standard oxygen therapy
 Settings where high-flow nasal cannula (HFNC) or helmet interfaces are available
and may be better tolerated with fewer leaks and better PEEP delivery

📝 Protocol Highlights: Tintinalli Framework + Evidence-

Based Caveats
 Phase / Severity Role of NIV / Non-Invasive Support
Careful NIV trial may be considered if PaO₂/FiO₂ >150–175,
Mild ARDS, early phase
in ICU setting with close monitoring
NIV is not routinely recommended; early intubation
Moderate-to-Severe ARDS
preferred to avoid delays and worsening outcomes
Immunocompromised / NIV or CPAP via face mask or helmet may reduce need for
Specific cases intubation and complications
Assess PaO₂/FiO₂ response in first hour, respiratory drive
Monitoring during NIV trial
(minute ventilation), tidal volumes (>9 ml/kg predicts failure)
Worsening hypoxemia, increased work of breathing, rising
Failure criteria
PaCO₂, hemodynamic instability → early transition to IMV

✅ Clinical Pearls (Tintinalli & Recent Evidence)

 Invasive ventilation remains the gold standard in ARDS management: low tidal
volumes, adequate PEEP, fluid restriction, prone positioning as tolerated.
 NIV may be appropriate in early, mild ARDS—but only in strictly controlled
settings with immediate access to intubation and continuous monitoring.
 High-risk of NIV failure—especially in moderate/severe cases or with high
respiratory drive—can lead to delayed intubation and worsened outcomes.
 Interfaces matter: Helmet NIV may be better tolerated and more effective than face
mask in maintaining PEEP.
 HFNC is an alternative that may outperform NIV in tolerability and mortality
outcomes in hypoxemic respiratory failure, including ARDS.

🔁 Summary

Tintinalli (9th Edition) acknowledges NIV as a potential option in select ARDS scenarios but
emphasizes that invasive low-volume ventilation remains the cornerstone of therapy. NIV
is a reserve strategy for carefully selected patients (especially mild ARDS,
immunosuppressed) and should be undertaken with caution—strict monitoring, prompt
identification of failure, and a low threshold for proceeding to invasive mechanical
ventilation.

(6) Pneumonia:
Pneumonia is an inflammatory condition of the lung primarily affecting the small air
sacs known as alveoli. Symptoms typically include some combination of productive
or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition
is variable.
Community-acquired pneumonia (CAP) is acquired in the community,[84][85] outside of
health care facilities.
Health care–associated pneumonia (HCAP) is an infection associated with recent
exposure to the health care system, including hospitals, outpatient clinics, nursing
homes, dialysis centers, chemotherapy treatment, or home care.
Clinical Recognition & Presentation
Tintinalli emphasizes:

 Common symptoms include fever, productive cough, dyspnea, chest pain, fatigue,
and altered mental status—particularly in elderly or severe disease.
 Physical exam may show crackles, bronchial breath sounds, and signs of
consolidation.

Guideline-aligned insights add that patterns of sputum (e.g. “rusty” in pneumococcal,

“currant-jelly” in Klebsiella), systemic symptoms, and epidemiological hints offer clues to
likely pathogens, although Tintinalli notes definitive differentiation is often not possible
clinically.

🔎 Diagnostic Workup
Tintinalli advocates:

 Chest radiography for confirming diagnosis when inpatient treatment is likely or if

there are risk factors/comorbidities.
 Point-of-care ultrasound (POCUS) may supplement evaluation, particularly for
pleural effusion or consolidation, though chest X-ray remains primary imaging.

Echoing broader evidence: CXR may be deferred in mild outpatient cases without
comorbidities; up to 50% of viral pneumonias may have minimal radiographic findings.

💊 Management Principles
✅ Empiric Antibiotic Therapy

Tintinalli recommends empiric treatment guided by severity and patient setting (outpatient vs
inpatient). Generally:

 Outpatient regimens typically include a macrolide or doxycycline, or beta-lactam

plus macrolide, depending on local resistance patterns.
 Inpatient treatment often combines a respiratory fluoroquinolone or beta-lactam
plus macrolide/atypical coverage.

This mirrors current guidelines: first-line outpatient in adults often amoxicillin, doxycycline,
or macrolide; inpatient care frequently beta-lactam plus macrolide or a respiratory
fluoroquinolone.

📉 Corticosteroids
Use of systemic corticosteroids for severe community-acquired pneumonia is discussed as
beneficial—shortening recovery time and reducing morbidity in select patients.

☁️Aspiration Pneumonia

Approach includes selective antibiotic use (e.g. clindamycin or beta-lactam plus anaerobic
coverage) and conservative management when aspiration pneumonitis is suspected, with
treatment tailored by clinical context .

🏥 Risk Stratification & Admission Criteria

Tintinalli emphasizes:

 Use clinical judgment supported by tools such as CURB-65 and Pneumonia Severity
Index (PSI) to determine hospitalization or ICU care.
 Evaluate for markers like altered mental status, hypotension, tachypnea, elevated
BUN, advanced age, comorbidities, or hypoxia for admission decisions.

These tools are consistent with validation studies: CURB-65 ≥ 2 often warrants hospital
admission; PSI similarly stratifies early risk and guides disposition.

🧪 Additional Diagnostics
Ordered as clinically indicated:

 Blood cultures, sputum Gram stain & culture, especially before antibiotics.
 Additional workup if presentation suggests viral pneumonia (e.g. influenza, RSV),
Legionella, or pulmonary embolism.
 Follow-up chest imaging recommended if patients have persistent symptoms, risk
factors (e.g., smokers, age >50), or concern for complications like effusion or
malignancy.

🧠 Complications and Follow-up

Key considerations include:

 Pleural effusion, empyema, or lung abscess—as summarised under adjacent chapters.

 Routine follow-up CXR in patients >50, smokers, or with slow resolution of
symptoms.
 Recognizing that bacterial pneumonia mortality and morbidity are higher in ICU
settings—emphasizing early, appropriate treatment and escalation strategies.
📋 Summary Table
Supporting Evidence-Based
Scenario Tintinalli Recommendations
Insights
Oral macrolide or doxycycline; beta- Local antibiogram-driven
Outpatient CAP
lactam combo empiric therapy
IV beta-lactam + macrolide or Broad-spectrum coverage
Inpatient CAP
respiratory fluoroquinolone including atypicals
Respiratory Admit, consider steroids, early CURB-65 ≥2, hypoxia, sepsis, or
failure / ICU aggressive care decompensation
Aspiration ANA coverage with clindamycin or Target anaerobes in high-risk
pneumonia β-lactam combos aspiration scenarios
CXR for most admissions; ultrasound Lower threshold for follow-up if
Imaging
adjunct slow to resolve
Detect persistent infiltrate,
Follow-up CXR for smokers, >50, slow recovery
effusion, or mass

✅ Clinical Pearls
 Time to antibiotics is critical: administer first dose promptly, ideally within the first
few hours of diagnosis.
 Antibiotic duration: short courses (5–7 days) are increasingly validated for common
pathogens in uncomplicated CAP.
 Steroid use may be beneficial in severe cases, but consider comorbidities such as
diabetes.
 Recognize aspiration presentations early; empiric anaerobic coverage is key when
risk factors exist.
 Use scoring systems like CURB-65/PSI to guide disposition, but always integrate
clinical gestalt.
 Always follow up in patients with risk factors or persistent illness—even after
discharge.